Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (252 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 07 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | SBI Comma Fund |
|---|---|
| 07 Jan 2013 | ₹100.00 |
| 25 Feb 2014 | ₹80.46 |
| 16 Apr 2015 | ₹122.15 |
| 03 Jun 2016 | ₹116.64 |
| 23 Jul 2017 | ₹171.82 |
| 10 Sep 2018 | ₹177.10 |
| 30 Oct 2019 | ₹182.54 |
| 17 Dec 2020 | ₹229.55 |
| 04 Feb 2022 | ₹367.31 |
| 26 Mar 2023 | ₹306.03 |
| 13 May 2024 | ₹464.27 |
| 02 Jul 2025 | ₹525.79 |
| 20 Aug 2026 | ₹588.62 |
| Metric | SBI · Direct NAV ₹128.03 Very High risk ★★☆☆☆ | Category median Sectoral/ Thematic · 252 funds |
|---|---|---|
| +12.79% | +7.23% | |
| +18.24% | +16.94% | |
| +12.69% | +14.70% | |
| +15.68% | +15.10% | |
| +13.90% | +14.07% | |
| +14.57% | — | |
| +16.56% | +17.59% | |
| +16.29% | +16.29% | |
| +16.31% | +16.00% | |
| Risk | ||
| 18.09% | 15.69% | |
| 0.65 | 0.52 | |
| 0.86 | 0.73 | |
| -40.75% | -23.08% | |
| Nifty 500 | — | |
| +5.31% | +4.66% | |
| 0.99 | 0.96 | |
| 109.7% | 109.1% | |
| 82.7% | 91.0% | |
| 1.47% | 1.14% | |
| ₹931.17Cr | ₹1,161Cr | |
| 0.50% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 52% | 45% | |
| Pradeep Kesavan · 2.7y | — | |
| 07 Jan 2013 | — | |
| 41 | — | |
| 42.7% | — | |
| 5.2% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.